Frontotemporal dementia (FTD) is a group of brain diseases caused by progressive nerve cell loss in the frontal and temporal lobes, the areas behind your forehead and near your ears. Unlike Alzheimer’s, which typically starts with memory loss, FTD usually strikes earlier in life and first disrupts personality, behavior, or language. About 60% of people diagnosed with FTD are between ages 45 and 60, making it one of the most common causes of dementia in younger adults.
FTD accounts for roughly 3% of all dementia cases when studies include people over 65, but that number jumps to about 10% in studies limited to people under 65. It is frequently misdiagnosed, sometimes for years, because its early symptoms can look like a psychiatric illness or simply a personality change.
The Three Main Types of FTD
FTD comes in three clinical subtypes, each targeting different brain functions. The most common is the behavioral variant (bvFTD), which changes how a person acts, relates to others, and manages emotions. The other two primarily affect language and fall under a broader category called primary progressive aphasia (PPA). These are the semantic variant, which erodes word meaning and object knowledge, and the nonfluent variant, which disrupts the physical ability to produce speech.
A third, less common language subtype called logopenic PPA causes trouble retrieving words and repeating sentences. It is more often linked to Alzheimer’s pathology than to the protein changes typical of FTD, but it still falls within the PPA spectrum.
How the Behavioral Variant Looks
Behavioral variant FTD is the form most likely to be mistaken for a psychiatric condition. It typically begins with shifts in social conduct that are obvious to family members but invisible on standard memory tests. A previously reserved person may start making inappropriate comments in public, spending money recklessly, or losing interest in hygiene. Others become profoundly apathetic, sitting for hours without initiating activity or conversation.
These changes reflect damage to the brain’s social cognition systems: the ability to read emotions, understand what other people are thinking, and feel empathy. People with bvFTD often lose the capacity to recognize when their behavior is upsetting someone. They may develop compulsive habits like eating only one food, hoarding objects, or repeating phrases. Overeating and strong cravings for sweets are especially common. Importantly, memory and spatial orientation tend to remain relatively intact in the early stages, which is a key reason this condition gets confused with depression, bipolar disorder, or midlife crisis.
How the Language Variants Look
The semantic variant gradually strips away a person’s ability to understand what words and objects mean. Speech itself stays fluent, but it becomes increasingly empty. Someone might say “the thing” instead of “fork,” or call a cat “an animal” because the more specific word has lost its meaning. They have particular trouble with less common words first. A person might still understand “dog” but draw a blank at “rhinoceros.” Over time, even everyday objects become unrecognizable.
The nonfluent variant works differently. Here, the problem is producing speech rather than understanding meaning. Talking becomes slow, effortful, and halting. People drop small grammatical words like “the” and “is,” or put words in the wrong order. They may mispronounce sounds, swap letters, or skip syllables. Understanding simple sentences stays intact early on, but complex sentences with multiple clauses become hard to follow. Behavioral changes and broader cognitive decline tend to appear later in this variant.
What Happens in the Brain
FTD results from the buildup of misfolded proteins in brain cells. The two proteins most often involved are tau and TDP-43. Tau normally helps stabilize the internal scaffolding of nerve cells. When it misfolds and clumps together, that scaffolding collapses and the cell dies. TDP-43 normally helps regulate how genes are read inside the cell. When it misfolds, it both loses that protective function and becomes directly toxic.
Which protein is involved determines the specific pattern of brain shrinkage and, to some extent, which symptoms appear. Brain imaging in people with bvFTD typically shows shrinkage in the prefrontal cortex and the front portions of the temporal lobes. The semantic variant shows pronounced temporal lobe shrinkage, while the nonfluent variant targets the left posterior frontal lobe, including the region responsible for coordinating speech movements.
Genetics and Family Risk
FTD has a stronger genetic component than most other dementias. Among familial cases, about 15% are caused by inherited mutations in one of three genes. The first, MAPT, provides the instructions for making tau protein. Mutations here directly cause abnormal tau to accumulate. The second, GRN, codes for a growth factor that helps keep brain cells healthy. When it is mutated, TDP-43 builds up instead. The third involves an abnormal repeat expansion in a gene called C9orf72, which is also linked to ALS (amyotrophic lateral sclerosis, or Lou Gehrig’s disease).
This overlap between FTD and ALS is clinically significant. Some people develop both conditions simultaneously, and when motor neuron disease accompanies FTD, the prognosis is considerably worse. Not all FTD is inherited, however. Many cases arise without any known family history, likely from a combination of genetic susceptibility and factors researchers are still working to identify.
How FTD Differs From Alzheimer’s
The most important distinction is where the disease starts. Alzheimer’s typically begins in brain regions responsible for forming new memories, so forgetting recent events is usually the first sign. FTD targets the frontal and temporal lobes first, so personality changes, poor judgment, or language difficulties appear well before any noticeable memory loss.
On cognitive testing, people with Alzheimer’s tend to score poorly on memory and orientation tasks, while people with FTD struggle more with language, executive skills like planning and organizing, and attention. In bvFTD specifically, neuropsychiatric changes are often the most prominent feature and can precede or mask any measurable cognitive decline. This is why someone with early FTD might perform normally on a standard dementia screening test, even as their family describes alarming behavioral changes at home.
Age at onset is another clue. While Alzheimer’s is overwhelmingly a disease of people over 65, FTD frequently begins in the 40s or 50s. People in that age range are rarely suspected of having dementia, which contributes to diagnostic delays that can stretch for years.
Disease Progression and Life Expectancy
FTD is a progressive condition with no current way to stop or reverse the underlying brain damage. The pace of decline varies by subtype. Median survival from symptom onset is roughly 10.5 years for the behavioral variant and about 12.6 years for the nonfluent language variant. Across all FTD subtypes without motor neuron disease, life expectancy ranges from 7 to 13 years after symptoms begin.
When FTD occurs alongside motor neuron disease (ALS), the timeline compresses sharply. Median survival in those cases is around 3 years, though some people live up to 5. The progression generally moves from the initial behavioral or language symptoms to broader cognitive impairment, increasing physical dependency, difficulty swallowing, and eventually the need for full-time care.
Treatment and Day-to-Day Management
There are currently no FDA-approved medications that slow or halt FTD. Treatment focuses on managing individual symptoms. Certain medications originally developed for other conditions can help reduce agitation, compulsive behaviors, or severe apathy, though responses vary widely from person to person. Speech therapy can help people with the language variants maintain communication skills for longer, and occupational therapy can support daily functioning as the disease progresses.
For caregivers, understanding the nature of the disease is often the most important intervention. The behavioral changes in FTD are not deliberate or controllable. A person who makes hurtful comments or refuses to engage with family is not choosing to act that way. Structuring the environment to reduce triggers for agitation, simplifying daily routines, and connecting with FTD-specific support groups can make a meaningful difference in quality of life for both the person with the diagnosis and the people around them.
Research into disease-modifying therapies is active. The National Institute on Aging has funded initiatives through 2025 aimed at developing new treatments, including gene-editing approaches targeting the known genetic mutations. Several early-stage clinical trials are underway, though a proven therapy that alters the course of FTD has not yet emerged.